Clinical Trial Update: Egrifta Replacement and Sleep Disordered Breathing

View source ↗

Summary

A clinical trial evaluating Egrifta (tesamorelin) for lipodystrophy, including sleep-disordered breathing considerations, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lipodystrophy

Drugs mentioned

• Egrifta (tesamorelin)

Snippet

Sponsor: Johns Hopkins University | Conditions: Lipodystrophy | Status: WITHDRAWN